REG - Verici Dx PLC - Clinical study validating PTRA test published

Verici DxAnnouncement

19/05/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260519:nRSS7958Ea&default-theme=true

RNS Number : 7958E  Verici Dx PLC  19 May 2026

 

Verici Dx plc

("Verici Dx" or the "Company")

 

Clinical study validating PTRA test published

 

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for
organ transplant, announces the publication of a peer-reviewed clinical
validation study of its Pre-Transplant Rejection Assessment ("PTRA") test. The
study, titled 'A Pre-Kidney Transplant Blood-Based Next-Generation Sequencing
Assay to Predict Early Acute Rejection' has been published in Kidney360
(https://journals.lww.com/kidney360/abstract/9900/a_pre_kidney_transplant_blood_based.941.aspx)
((1)). The PTRA test is commercially marketed by Thermo Fisher
Scientific((2)).

 

The study showed that the PTRA test outperformed conventional risk assessment
tools in the ability to predict Early Acute Rejection ("EAR") in the first two
months following transplant, enabling clinicians to identify patients who may
benefit from safe minimisation of therapy while effectively managing risk of
early rejection. Currently, kidney transplant recipients receive standardised
immunosuppressive regimens, with more aggressive therapy reserved for patients
perceived as high-risk. However, these conventional risk features have limited
predictive value, which can lead to unnecessary over-suppression and risks
related to toxicity, infections and malignancy.

 

(1)  Published by Wolters Kluwer Health, Inc. on behalf of the American
Society of Nephrology

(2)  The PTRA test is a laboratory developed test that is used for clinical
purposes by the CLIA-certified laboratory performing the test. The test has
not been cleared or approved by the U.S. Food and Drug Administration ("FDA")
or CE marked in the EU as an in vitro diagnostic test.

 

Beatrice Concepcion, Medical Director, Kidney and Pancreas Transplant,
University of Chicago Medicine, said: "The data from this study demonstrates
that PTRA provides clinically meaningful, recipient-specific risk
stratification. This creates the opportunity to identify low-risk patients in
whom we may safely reduce immunosuppressive therapy, addressing a
long-standing unmet need in transplant medicine. By aiding clinicians in risk
assessing recipients, PTRA offers an advancement in support for how we manage
immunosuppression."

 

Patti Connolly, Chief Operating Officer of Verici Dx, said: "We are delighted
that the publication of this study further validates PTRA for predicting EAR
in kidney transplant recipients. The test enables a more personalised approach
to immunosuppression management during the critical early post-transplant
period and supports clinicians in the identification of patients at low
immunologic risk of EAR, which may allow the recipient to be considered for
less aggressive immunosuppressive regimens."

 

 Verici Dx plc                                 www.vericidx.com (https://vericidx.com/)

 Sara Barrington, CEO                          Via Walbrook PR

 Singer Capital Markets (Nominated adviser, Joint Broker)                     Tel: +44 (0)20 7496 3000
 Alex Bond / Russell Cook / Jalini Kalaravy

 Oberon Capital (Joint Broker)                 Tel: +44 (0)20 3179 0500
 Mike Seabrook / Adam Pollock

 Walbrook PR (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com
 Alice Woodings / Rachel Broad                 Mob: +44 (0)7407 804 654 / +44 (0)7747 515 393

 

 

Verici Dx

Verici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care
for transplant patients. The company combines multiomic analysis with
proprietary artificial intelligence to deliver predictive, actionable,
data-driven intelligence that reflects the complexity and heterogeneity of
transplant patients, enabling clinicians to optimise therapy, guide biopsy
decisions, and stratify risk with greater confidence.

 

Operating at the intersection of laboratory and data science, Verici Dx
develops complex models that answer the clinical questions that matter most
with unrivaled clarity and precision. All tests are built to rigorous
scientific standards, validated across inclusive, and real-world patient
populations to ensure clinical relevance and reliability. Verici Dx's lead
product, Tutivia™, is a post-kidney transplant test focused on early
detection of acute rejection.

 

The company is UK headquartered in Cardiff for the UK, and in Franklin,
Tennessee for the U.S. For more information, please visit
https://vericidx.com/ (https://vericidx.com/) and follow us on LinkedIn
(https://www.linkedin.com/company/verici-dx/) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGPUMPAUPQGQR



            Copyright 2019 Regulatory News Service, all rights reserved